N
NeuroMed Pharmaceuticals
Calcium channel blockers for chronic pain treatment
About NeuroMed Pharmaceuticals
NeuroMed Pharmaceuticals was a biopharmaceutical company focused on developing treatments for chronic pain by targeting calcium channels. The company was founded in 1998 in Vancouver, Canada, by Dr. Terrance Snutch, a professor at the University of British Columbia. NeuroMed operated on a "fusion" business model, which combined high-risk, high-reward drug discovery with lower-risk specialty pharmaceutical development.
The company's research focused on developing N-type and T-type calcium channel blockers to treat chronic pain, epilepsy, and hypertension. One of its key product candidates was NMED-1077, also known as OROS Hydromorphone, a once-daily, extended-release formulation of hydromorphone for chronic moderate-to-severe pain. NeuroMed acquired the U.S. rights for this product from Johnson & Johnson's subsidiary, ALZA Corporation, and advanced it to Phase 3 clinical trials. Additionally, NeuroMed had a research collaboration with Merck to discover novel compounds targeting N-type calcium channels, though this partnership was terminated in 2009 after the molecules developed did not meet the criteria for human clinical trials.
Throughout its operation, NeuroMed secured significant funding, raising a total of $126 million over several financing rounds, with its Series E round in 2007 raising $53.3 million. Key investors included MPM Capital, GrowthWorks Capital, Royal Bank of Canada, and BDC Venture Capital. The company was formerly known as Neuromed Technologie before changing its name in March 2006. Ultimately, Neuromed Pharmaceuticals was acquired and is now considered a deadpooled company.
Source: Dealroom company dataNews
Open roles
NeuroMed Pharmaceuticals in the New Haven ecosystem
The NeuroMed Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
- MCMDS Capital
Series B and later5 investors entered at this stage
Business Development Bank of Canada
MPM BioImpact
Royal Bank of Canada
GrowthWorks Capital
James Richardson & Sons
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about NeuroMed Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See NeuroMed Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.